Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
So far, Sciwind has established five first-in-class or best-in-class innovative drugs at different stages of development. We will also pay close attention to industry development and patient needs, and steadily advance existing projects. As we progress, we continue to conduct new research and provide more treatments for patients.